Literature DB >> 10523371

Cyclooxygenase-2 modulates afferent arteriolar responses to increases in pressure.

A Ichihara1, J D Imig, L G Navar.   

Abstract

This study was designed to examine the contribution of cyclooxygenase-2 (COX-2) in the afferent arteriolar autoregulatory responses to increases in perfusion pressure and its relationship with neuronal nitric oxide synthase (nNOS). In rat kidneys, afferent arteriolar diameter responses to increases in perfusion pressure were assessed in vitro with the blood-perfused juxtamedullary nephron technique. Basal afferent arteriolar diameter at 100 mm Hg averaged 21.0+/-1.2 microm (n=7), and the vasoconstrictor response to increasing perfusion pressure to 160 mm Hg averaged 18.4+/-1.2%. Superfusion with the COX-2 inhibitor NS398 (10 micromol/L) did not influence basal diameters, but it did significantly enhance the vasoconstrictor response to the increase in perfusion pressure (32.9+/-4.0%). In contrast to previous findings that the nNOS inhibitor S-methyl-L-thiocitrulline (10 micromol/L) enhanced afferent arteriolar autoregulatory responses in normal rat kidneys, in this study, administration of 10 micromol/L S-methyl-L-thiocitrulline did not further modulate the vasoconstrictor response to increases in perfusion pressure in the NS398-treated kidneys of normal rats (31.8+/-4.7%). When tubuloglomerular feedback activity was interrupted by papillectomy and the addition of 50 micromol/L furosemide to the blood perfusate (n=5 for each), the afferent arteriolar constrictor responses to increasing perfusion pressure to 160 mm Hg averaged 7.9+/-0.9% and 10.7+/-0.7%, respectively, and they were significantly attenuated compared with the responses observed in control kidneys. NS398 treatment did not modulate the afferent arteriolar autoregulatory responses in papillectomized or furosemide-treated kidneys. These results indicate that COX-2-derived metabolites contribute to the nNOS modulation of pressure-mediated afferent arteriolar autoregulatory responses.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10523371     DOI: 10.1161/01.hyp.34.4.843

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  9 in total

Review 1.  Renal renin-angiotensin system.

Authors:  Atsuhiro Ichihara; Hiroyuki Kobori; Akira Nishiyama; L Gabriel Navar
Journal:  Contrib Nephrol       Date:  2004       Impact factor: 1.580

Review 2.  Renal autoregulation in health and disease.

Authors:  Mattias Carlström; Christopher S Wilcox; William J Arendshorst
Journal:  Physiol Rev       Date:  2015-04       Impact factor: 37.312

3.  Upregulation of cyclooxygenase-2 expression in porcine macula densa with chronic nitric oxide synthase inhibition.

Authors:  M Kommareddy; R M McAllister; V K Ganjam; J R Turk; M Harold Laughlin
Journal:  Vet Pathol       Date:  2010-12-15       Impact factor: 2.221

4.  Renal hyperfiltration related to diabetes mellitus and obesity in human disease.

Authors:  Alexa N Sasson; David Zi Cherney
Journal:  World J Diabetes       Date:  2012-01-15

5.  Immunohistochemical and functional correlations of renal cyclooxygenase-2 in experimental diabetes.

Authors:  R Komers; J N Lindsley; T T Oyama; W E Schutzer; J F Reed; S L Mader; S Anderson
Journal:  J Clin Invest       Date:  2001-04       Impact factor: 14.808

6.  Cyclooxygenase 2 inhibition suppresses tubuloglomerular feedback: roles of thromboxane receptors and nitric oxide.

Authors:  Magali Araujo; William J Welch
Journal:  Am J Physiol Renal Physiol       Date:  2009-01-14

Review 7.  Ibuprofen: pharmacology, efficacy and safety.

Authors:  K D Rainsford
Journal:  Inflammopharmacology       Date:  2009-11-21       Impact factor: 4.473

Review 8.  Cyclo-Oxygenase (COX) Inhibitors and Cardiovascular Risk: Are Non-Steroidal Anti-Inflammatory Drugs Really Anti-Inflammatory?

Authors:  Shanzana Khan; Karen L Andrews; Jaye P F Chin-Dusting
Journal:  Int J Mol Sci       Date:  2019-08-30       Impact factor: 5.923

9.  Selective cyclooxygenase-2 inhibition protects against myocardial damage in experimental acute ischemia.

Authors:  Alberto Carnieto; Paulo Magno Martins Dourado; Protásio Lemos da Luz; Antonio Carlos Palandri Chagas
Journal:  Clinics (Sao Paulo)       Date:  2009       Impact factor: 2.365

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.